PCSK9 and hepatocellular carcinoma: PCSK9 displays oncogenic actions in cancer [26], including gastric cancer [27], esophageal cancer [28], prostate cancer [29–31], breast cancer [32], ovarian cancer [33], lung cancer [34–37], hepatocellular carcinoma [38, 39], and melanoma [40, 41].